CL2022003703A1 - Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos - Google Patents

Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos

Info

Publication number
CL2022003703A1
CL2022003703A1 CL2022003703A CL2022003703A CL2022003703A1 CL 2022003703 A1 CL2022003703 A1 CL 2022003703A1 CL 2022003703 A CL2022003703 A CL 2022003703A CL 2022003703 A CL2022003703 A CL 2022003703A CL 2022003703 A1 CL2022003703 A1 CL 2022003703A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
compositions containing
manufacturing methods
antibiotic compounds
compounds
Prior art date
Application number
CL2022003703A
Other languages
English (en)
Inventor
Gerusz Vincent
Bravo Juan
Tatsis Vasileios
Sunose Mihiro
Finn Terry
Pohin Danig
Regenass Pierre-Michel
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of CL2022003703A1 publication Critical patent/CL2022003703A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos de la estructura general (I), que son adecuados como compuestos antibióticos para el tratamiento de infecciones por N. gonorrhoeae e infecciones relacionadas.
CL2022003703A 2018-11-12 2022-12-22 Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos CL2022003703A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18205619 2018-11-12
EP18213016 2018-12-17

Publications (1)

Publication Number Publication Date
CL2022003703A1 true CL2022003703A1 (es) 2023-06-09

Family

ID=68610175

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021001244A CL2021001244A1 (es) 2018-11-12 2021-05-12 Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos
CL2022003703A CL2022003703A1 (es) 2018-11-12 2022-12-22 Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021001244A CL2021001244A1 (es) 2018-11-12 2021-05-12 Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos

Country Status (15)

Country Link
US (1) US20230035837A1 (es)
EP (1) EP3880675A1 (es)
JP (1) JP2022506957A (es)
KR (1) KR20210093292A (es)
CN (1) CN113272302A (es)
AU (1) AU2019380568A1 (es)
BR (1) BR112021009106A2 (es)
CA (1) CA3119390A1 (es)
CL (2) CL2021001244A1 (es)
IL (1) IL282950A (es)
MX (1) MX2021005535A (es)
PH (1) PH12021551058A1 (es)
SG (1) SG11202104863RA (es)
TN (1) TN2021000092A1 (es)
WO (1) WO2020099341A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187329A1 (en) * 2021-03-03 2022-09-09 The Board Of Trustees Of The University Of Illinois Fabi inhibitors for gram-negative pathogens
CA3223459A1 (en) 2021-06-23 2022-12-29 Vincent Gerusz Novel compounds and their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
WO2003088897A2 (en) 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
DK1828167T3 (da) 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
WO2007067416A2 (en) 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CN101415701A (zh) * 2005-12-05 2009-04-22 Affinium医药公司 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
JO3611B1 (ar) 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
CA2849057C (en) 2011-09-19 2021-05-11 Vitas Pharma Research Pvt Ltd Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
US9062002B2 (en) 2011-12-02 2015-06-23 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as FabI inhibitors
TR201909016T4 (tr) 2012-06-19 2019-07-22 Debiopharm Int Sa (E)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamidin ön ilaç türevleri.
BR112015002923B1 (pt) * 2012-08-10 2021-09-21 Janssen Sciences Ireland Uc Compostos antibacterianos, composição farmacêutica e processo de preparação dos mesmos
WO2015048662A2 (en) 2013-09-30 2015-04-02 X-Rx Discovery, Inc. Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

Also Published As

Publication number Publication date
CA3119390A1 (en) 2020-05-22
CL2021001244A1 (es) 2021-11-19
IL282950A (en) 2021-06-30
WO2020099341A1 (en) 2020-05-22
BR112021009106A2 (pt) 2021-08-10
JP2022506957A (ja) 2022-01-17
TN2021000092A1 (en) 2023-01-05
CN113272302A (zh) 2021-08-17
MX2021005535A (es) 2021-09-08
AU2019380568A1 (en) 2021-06-17
EP3880675A1 (en) 2021-09-22
US20230035837A1 (en) 2023-02-02
SG11202104863RA (en) 2021-06-29
PH12021551058A1 (en) 2021-11-22
KR20210093292A (ko) 2021-07-27

Similar Documents

Publication Publication Date Title
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
ECSP19057713A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
CO2019013016A2 (es) Inhibidores pirazólicos de magl
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
CO2019013823A2 (es) Compuestos heteroaromáticos como inhibidores de vanina
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2021002225A2 (es) Compuestos heteroaromáticos como inhibidores de vanina
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CL2018003109A1 (es) Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.
EA202191343A1 (ru) Антибиотические соединения, способы их получения, фармацевтические композиции, содержащие их, и их применение
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1